GENER CRUZ: Open Payments
NPI 1811612310 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,711 in 85 payments from 15 companies in 2025. Trend: 2023 $91 · 2024 $1,563 · 2025 $1,711
Food & beverage: $1,711
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 27 | $568 |
| Janssen Biotech, Inc. | 20 | $263 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 12 | $251 |
| Phathom Pharmaceuticals, Inc. | 5 | $130 |
| Novo Nordisk Inc | 5 | $94 |
| Madrigal Pharmaceuticals | 2 | $84 |
| ORPHALAN INC | 2 | $56 |
| Gilead Sciences, Inc. | 2 | $50 |
| Lilly USA, LLC | 2 | $46 |
| GENZYME CORPORATION | 2 | $44 |
Products named: SKYRIZI, TREMFYA, RINVOQ, VOQUEZNA, XIFAXAN, RELISTOR, Wegovy, REZDIFFRA.
Industry payments across NV — which companies pay providers there.
